nodes	percent_of_prediction	percent_of_DWPC	metapath
Escitalopram—CYP2C19—Gefitinib—lung cancer	0.0559	0.124	CbGbCtD
Escitalopram—CYP2C19—Teniposide—lung cancer	0.0542	0.12	CbGbCtD
Escitalopram—CYP2D6—Gefitinib—lung cancer	0.0425	0.0942	CbGbCtD
Escitalopram—CYP2D6—Vinorelbine—lung cancer	0.0328	0.0726	CbGbCtD
Escitalopram—CYP3A4—Topotecan—lung cancer	0.0296	0.0655	CbGbCtD
Escitalopram—CYP3A4—Gefitinib—lung cancer	0.027	0.0599	CbGbCtD
Escitalopram—CYP3A4—Teniposide—lung cancer	0.0262	0.0581	CbGbCtD
Escitalopram—CYP2D6—Erlotinib—lung cancer	0.0251	0.0557	CbGbCtD
Escitalopram—CYP3A4—Vinorelbine—lung cancer	0.0208	0.0462	CbGbCtD
Escitalopram—CYP2D6—Vinblastine—lung cancer	0.0202	0.0447	CbGbCtD
Escitalopram—CYP3A4—Crizotinib—lung cancer	0.0166	0.0367	CbGbCtD
Escitalopram—CYP3A4—Erlotinib—lung cancer	0.016	0.0354	CbGbCtD
Escitalopram—CYP3A4—Paclitaxel—lung cancer	0.0146	0.0324	CbGbCtD
Escitalopram—CYP3A4—Irinotecan—lung cancer	0.0144	0.032	CbGbCtD
Escitalopram—CYP3A4—Vinblastine—lung cancer	0.0128	0.0284	CbGbCtD
Escitalopram—CYP2D6—Doxorubicin—lung cancer	0.0124	0.0275	CbGbCtD
Escitalopram—CYP3A4—Etoposide—lung cancer	0.0116	0.0256	CbGbCtD
Escitalopram—CYP3A4—Docetaxel—lung cancer	0.0106	0.0234	CbGbCtD
Escitalopram—CYP3A4—Doxorubicin—lung cancer	0.00789	0.0175	CbGbCtD
Escitalopram—Citalopram—CYP2E1—lung cancer	0.00371	0.656	CrCbGaD
Escitalopram—Citalopram—ABCB1—lung cancer	0.00195	0.344	CrCbGaD
Escitalopram—Feeling abnormal—Etoposide—lung cancer	6.97e-05	0.000165	CcSEcCtD
Escitalopram—Hyperglycaemia—Doxorubicin—lung cancer	6.96e-05	0.000165	CcSEcCtD
Escitalopram—Diarrhoea—Irinotecan—lung cancer	6.96e-05	0.000164	CcSEcCtD
Escitalopram—Pneumonia—Doxorubicin—lung cancer	6.92e-05	0.000164	CcSEcCtD
Escitalopram—Gastrointestinal pain—Etoposide—lung cancer	6.92e-05	0.000164	CcSEcCtD
Escitalopram—Shock—Docetaxel—lung cancer	6.92e-05	0.000163	CcSEcCtD
Escitalopram—Nervous system disorder—Docetaxel—lung cancer	6.89e-05	0.000163	CcSEcCtD
Escitalopram—Thrombocytopenia—Docetaxel—lung cancer	6.88e-05	0.000163	CcSEcCtD
Escitalopram—Infestation—Doxorubicin—lung cancer	6.88e-05	0.000163	CcSEcCtD
Escitalopram—Infestation NOS—Doxorubicin—lung cancer	6.88e-05	0.000163	CcSEcCtD
Escitalopram—Visual impairment—Methotrexate—lung cancer	6.87e-05	0.000162	CcSEcCtD
Escitalopram—Tachycardia—Docetaxel—lung cancer	6.86e-05	0.000162	CcSEcCtD
Escitalopram—Feeling abnormal—Paclitaxel—lung cancer	6.84e-05	0.000162	CcSEcCtD
Escitalopram—Skin disorder—Docetaxel—lung cancer	6.83e-05	0.000161	CcSEcCtD
Escitalopram—Stevens-Johnson syndrome—Doxorubicin—lung cancer	6.82e-05	0.000161	CcSEcCtD
Escitalopram—Hypersensitivity—Cisplatin—lung cancer	6.8e-05	0.000161	CcSEcCtD
Escitalopram—Gastrointestinal pain—Paclitaxel—lung cancer	6.78e-05	0.00016	CcSEcCtD
Escitalopram—Diarrhoea—Gemcitabine—lung cancer	6.78e-05	0.00016	CcSEcCtD
Escitalopram—Erythema multiforme—Methotrexate—lung cancer	6.74e-05	0.000159	CcSEcCtD
Escitalopram—Neuropathy peripheral—Doxorubicin—lung cancer	6.74e-05	0.000159	CcSEcCtD
Escitalopram—Dizziness—Irinotecan—lung cancer	6.73e-05	0.000159	CcSEcCtD
Escitalopram—Urticaria—Etoposide—lung cancer	6.72e-05	0.000159	CcSEcCtD
Escitalopram—Stomatitis—Doxorubicin—lung cancer	6.71e-05	0.000159	CcSEcCtD
Escitalopram—Jaundice—Doxorubicin—lung cancer	6.71e-05	0.000159	CcSEcCtD
Escitalopram—Anorexia—Docetaxel—lung cancer	6.7e-05	0.000158	CcSEcCtD
Escitalopram—Body temperature increased—Etoposide—lung cancer	6.69e-05	0.000158	CcSEcCtD
Escitalopram—Abdominal pain—Etoposide—lung cancer	6.69e-05	0.000158	CcSEcCtD
Escitalopram—Conjunctivitis—Doxorubicin—lung cancer	6.69e-05	0.000158	CcSEcCtD
Escitalopram—Urinary tract infection—Doxorubicin—lung cancer	6.69e-05	0.000158	CcSEcCtD
Escitalopram—Eye disorder—Methotrexate—lung cancer	6.67e-05	0.000158	CcSEcCtD
Escitalopram—Tinnitus—Methotrexate—lung cancer	6.65e-05	0.000157	CcSEcCtD
Escitalopram—Asthenia—Cisplatin—lung cancer	6.63e-05	0.000157	CcSEcCtD
Escitalopram—Cardiac disorder—Methotrexate—lung cancer	6.62e-05	0.000156	CcSEcCtD
Escitalopram—Sweating—Doxorubicin—lung cancer	6.6e-05	0.000156	CcSEcCtD
Escitalopram—Urticaria—Paclitaxel—lung cancer	6.59e-05	0.000156	CcSEcCtD
Escitalopram—Hypotension—Docetaxel—lung cancer	6.57e-05	0.000155	CcSEcCtD
Escitalopram—Haematuria—Doxorubicin—lung cancer	6.56e-05	0.000155	CcSEcCtD
Escitalopram—Body temperature increased—Paclitaxel—lung cancer	6.56e-05	0.000155	CcSEcCtD
Escitalopram—Abdominal pain—Paclitaxel—lung cancer	6.56e-05	0.000155	CcSEcCtD
Escitalopram—Hepatobiliary disease—Doxorubicin—lung cancer	6.51e-05	0.000154	CcSEcCtD
Escitalopram—Epistaxis—Doxorubicin—lung cancer	6.49e-05	0.000153	CcSEcCtD
Escitalopram—Angiopathy—Methotrexate—lung cancer	6.47e-05	0.000153	CcSEcCtD
Escitalopram—Vomiting—Irinotecan—lung cancer	6.47e-05	0.000153	CcSEcCtD
Escitalopram—Sinusitis—Doxorubicin—lung cancer	6.45e-05	0.000153	CcSEcCtD
Escitalopram—Immune system disorder—Methotrexate—lung cancer	6.44e-05	0.000152	CcSEcCtD
Escitalopram—Mediastinal disorder—Methotrexate—lung cancer	6.43e-05	0.000152	CcSEcCtD
Escitalopram—Agranulocytosis—Doxorubicin—lung cancer	6.42e-05	0.000152	CcSEcCtD
Escitalopram—Rash—Irinotecan—lung cancer	6.41e-05	0.000152	CcSEcCtD
Escitalopram—Dermatitis—Irinotecan—lung cancer	6.41e-05	0.000151	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Docetaxel—lung cancer	6.41e-05	0.000151	CcSEcCtD
Escitalopram—Chills—Methotrexate—lung cancer	6.4e-05	0.000151	CcSEcCtD
Escitalopram—Headache—Irinotecan—lung cancer	6.37e-05	0.000151	CcSEcCtD
Escitalopram—Insomnia—Docetaxel—lung cancer	6.36e-05	0.00015	CcSEcCtD
Escitalopram—Diarrhoea—Cisplatin—lung cancer	6.32e-05	0.000149	CcSEcCtD
Escitalopram—Paraesthesia—Docetaxel—lung cancer	6.31e-05	0.000149	CcSEcCtD
Escitalopram—Alopecia—Methotrexate—lung cancer	6.3e-05	0.000149	CcSEcCtD
Escitalopram—Vomiting—Gemcitabine—lung cancer	6.3e-05	0.000149	CcSEcCtD
Escitalopram—Bradycardia—Doxorubicin—lung cancer	6.29e-05	0.000149	CcSEcCtD
Escitalopram—Dyspnoea—Docetaxel—lung cancer	6.27e-05	0.000148	CcSEcCtD
Escitalopram—Somnolence—Docetaxel—lung cancer	6.25e-05	0.000148	CcSEcCtD
Escitalopram—Mental disorder—Methotrexate—lung cancer	6.25e-05	0.000148	CcSEcCtD
Escitalopram—Rash—Gemcitabine—lung cancer	6.25e-05	0.000148	CcSEcCtD
Escitalopram—Dermatitis—Gemcitabine—lung cancer	6.24e-05	0.000148	CcSEcCtD
Escitalopram—Hypersensitivity—Etoposide—lung cancer	6.23e-05	0.000147	CcSEcCtD
Escitalopram—Malnutrition—Methotrexate—lung cancer	6.21e-05	0.000147	CcSEcCtD
Escitalopram—Erythema—Methotrexate—lung cancer	6.21e-05	0.000147	CcSEcCtD
Escitalopram—Haemoglobin—Doxorubicin—lung cancer	6.21e-05	0.000147	CcSEcCtD
Escitalopram—Headache—Gemcitabine—lung cancer	6.21e-05	0.000147	CcSEcCtD
Escitalopram—Rhinitis—Doxorubicin—lung cancer	6.19e-05	0.000146	CcSEcCtD
Escitalopram—Dyspepsia—Docetaxel—lung cancer	6.19e-05	0.000146	CcSEcCtD
Escitalopram—Hepatitis—Doxorubicin—lung cancer	6.18e-05	0.000146	CcSEcCtD
Escitalopram—Haemorrhage—Doxorubicin—lung cancer	6.18e-05	0.000146	CcSEcCtD
Escitalopram—Hypoaesthesia—Doxorubicin—lung cancer	6.15e-05	0.000145	CcSEcCtD
Escitalopram—Pharyngitis—Doxorubicin—lung cancer	6.13e-05	0.000145	CcSEcCtD
Escitalopram—Decreased appetite—Docetaxel—lung cancer	6.11e-05	0.000144	CcSEcCtD
Escitalopram—Hypersensitivity—Paclitaxel—lung cancer	6.11e-05	0.000144	CcSEcCtD
Escitalopram—Urinary tract disorder—Doxorubicin—lung cancer	6.1e-05	0.000144	CcSEcCtD
Escitalopram—Oedema peripheral—Doxorubicin—lung cancer	6.08e-05	0.000144	CcSEcCtD
Escitalopram—Dysgeusia—Methotrexate—lung cancer	6.08e-05	0.000144	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Docetaxel—lung cancer	6.07e-05	0.000143	CcSEcCtD
Escitalopram—Asthenia—Etoposide—lung cancer	6.07e-05	0.000143	CcSEcCtD
Escitalopram—Connective tissue disorder—Doxorubicin—lung cancer	6.07e-05	0.000143	CcSEcCtD
Escitalopram—Fatigue—Docetaxel—lung cancer	6.06e-05	0.000143	CcSEcCtD
Escitalopram—Urethral disorder—Doxorubicin—lung cancer	6.05e-05	0.000143	CcSEcCtD
Escitalopram—Nausea—Irinotecan—lung cancer	6.04e-05	0.000143	CcSEcCtD
Escitalopram—Pain—Docetaxel—lung cancer	6.01e-05	0.000142	CcSEcCtD
Escitalopram—Constipation—Docetaxel—lung cancer	6.01e-05	0.000142	CcSEcCtD
Escitalopram—Back pain—Methotrexate—lung cancer	6.01e-05	0.000142	CcSEcCtD
Escitalopram—Pruritus—Etoposide—lung cancer	5.99e-05	0.000141	CcSEcCtD
Escitalopram—Visual impairment—Doxorubicin—lung cancer	5.95e-05	0.000141	CcSEcCtD
Escitalopram—Asthenia—Paclitaxel—lung cancer	5.95e-05	0.000141	CcSEcCtD
Escitalopram—Nausea—Gemcitabine—lung cancer	5.88e-05	0.000139	CcSEcCtD
Escitalopram—Vomiting—Cisplatin—lung cancer	5.87e-05	0.000139	CcSEcCtD
Escitalopram—Pruritus—Paclitaxel—lung cancer	5.87e-05	0.000139	CcSEcCtD
Escitalopram—Vision blurred—Methotrexate—lung cancer	5.85e-05	0.000138	CcSEcCtD
Escitalopram—Erythema multiforme—Doxorubicin—lung cancer	5.84e-05	0.000138	CcSEcCtD
Escitalopram—Rash—Cisplatin—lung cancer	5.82e-05	0.000138	CcSEcCtD
Escitalopram—Dermatitis—Cisplatin—lung cancer	5.82e-05	0.000137	CcSEcCtD
Escitalopram—Feeling abnormal—Docetaxel—lung cancer	5.79e-05	0.000137	CcSEcCtD
Escitalopram—Diarrhoea—Etoposide—lung cancer	5.79e-05	0.000137	CcSEcCtD
Escitalopram—Eye disorder—Doxorubicin—lung cancer	5.77e-05	0.000136	CcSEcCtD
Escitalopram—Ill-defined disorder—Methotrexate—lung cancer	5.76e-05	0.000136	CcSEcCtD
Escitalopram—Tinnitus—Doxorubicin—lung cancer	5.76e-05	0.000136	CcSEcCtD
Escitalopram—Gastrointestinal pain—Docetaxel—lung cancer	5.75e-05	0.000136	CcSEcCtD
Escitalopram—Anaemia—Methotrexate—lung cancer	5.74e-05	0.000136	CcSEcCtD
Escitalopram—Cardiac disorder—Doxorubicin—lung cancer	5.73e-05	0.000135	CcSEcCtD
Escitalopram—Flushing—Doxorubicin—lung cancer	5.73e-05	0.000135	CcSEcCtD
Escitalopram—Diarrhoea—Paclitaxel—lung cancer	5.68e-05	0.000134	CcSEcCtD
Escitalopram—Angiopathy—Doxorubicin—lung cancer	5.6e-05	0.000132	CcSEcCtD
Escitalopram—Malaise—Methotrexate—lung cancer	5.6e-05	0.000132	CcSEcCtD
Escitalopram—Dizziness—Etoposide—lung cancer	5.59e-05	0.000132	CcSEcCtD
Escitalopram—Immune system disorder—Doxorubicin—lung cancer	5.58e-05	0.000132	CcSEcCtD
Escitalopram—Vertigo—Methotrexate—lung cancer	5.58e-05	0.000132	CcSEcCtD
Escitalopram—Mediastinal disorder—Doxorubicin—lung cancer	5.57e-05	0.000132	CcSEcCtD
Escitalopram—Abdominal pain—Docetaxel—lung cancer	5.56e-05	0.000131	CcSEcCtD
Escitalopram—Body temperature increased—Docetaxel—lung cancer	5.56e-05	0.000131	CcSEcCtD
Escitalopram—Leukopenia—Methotrexate—lung cancer	5.56e-05	0.000131	CcSEcCtD
Escitalopram—Chills—Doxorubicin—lung cancer	5.54e-05	0.000131	CcSEcCtD
Escitalopram—Arrhythmia—Doxorubicin—lung cancer	5.52e-05	0.00013	CcSEcCtD
Escitalopram—Dizziness—Paclitaxel—lung cancer	5.49e-05	0.00013	CcSEcCtD
Escitalopram—Nausea—Cisplatin—lung cancer	5.49e-05	0.00013	CcSEcCtD
Escitalopram—Alopecia—Doxorubicin—lung cancer	5.46e-05	0.000129	CcSEcCtD
Escitalopram—Cough—Methotrexate—lung cancer	5.42e-05	0.000128	CcSEcCtD
Escitalopram—Mental disorder—Doxorubicin—lung cancer	5.41e-05	0.000128	CcSEcCtD
Escitalopram—Convulsion—Methotrexate—lung cancer	5.38e-05	0.000127	CcSEcCtD
Escitalopram—Vomiting—Etoposide—lung cancer	5.38e-05	0.000127	CcSEcCtD
Escitalopram—Malnutrition—Doxorubicin—lung cancer	5.38e-05	0.000127	CcSEcCtD
Escitalopram—Erythema—Doxorubicin—lung cancer	5.38e-05	0.000127	CcSEcCtD
Escitalopram—Rash—Etoposide—lung cancer	5.33e-05	0.000126	CcSEcCtD
Escitalopram—Dermatitis—Etoposide—lung cancer	5.33e-05	0.000126	CcSEcCtD
Escitalopram—Headache—Etoposide—lung cancer	5.3e-05	0.000125	CcSEcCtD
Escitalopram—Flatulence—Doxorubicin—lung cancer	5.3e-05	0.000125	CcSEcCtD
Escitalopram—Myalgia—Methotrexate—lung cancer	5.29e-05	0.000125	CcSEcCtD
Escitalopram—Arthralgia—Methotrexate—lung cancer	5.29e-05	0.000125	CcSEcCtD
Escitalopram—Chest pain—Methotrexate—lung cancer	5.29e-05	0.000125	CcSEcCtD
Escitalopram—Tension—Doxorubicin—lung cancer	5.28e-05	0.000125	CcSEcCtD
Escitalopram—Vomiting—Paclitaxel—lung cancer	5.27e-05	0.000125	CcSEcCtD
Escitalopram—Dysgeusia—Doxorubicin—lung cancer	5.26e-05	0.000124	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	5.25e-05	0.000124	CcSEcCtD
Escitalopram—Rash—Paclitaxel—lung cancer	5.23e-05	0.000124	CcSEcCtD
Escitalopram—Dermatitis—Paclitaxel—lung cancer	5.23e-05	0.000124	CcSEcCtD
Escitalopram—Discomfort—Methotrexate—lung cancer	5.22e-05	0.000123	CcSEcCtD
Escitalopram—Nervousness—Doxorubicin—lung cancer	5.22e-05	0.000123	CcSEcCtD
Escitalopram—Back pain—Doxorubicin—lung cancer	5.2e-05	0.000123	CcSEcCtD
Escitalopram—Headache—Paclitaxel—lung cancer	5.2e-05	0.000123	CcSEcCtD
Escitalopram—Hypersensitivity—Docetaxel—lung cancer	5.18e-05	0.000122	CcSEcCtD
Escitalopram—Muscle spasms—Doxorubicin—lung cancer	5.17e-05	0.000122	CcSEcCtD
Escitalopram—Confusional state—Methotrexate—lung cancer	5.11e-05	0.000121	CcSEcCtD
Escitalopram—Anaphylactic shock—Methotrexate—lung cancer	5.07e-05	0.00012	CcSEcCtD
Escitalopram—Vision blurred—Doxorubicin—lung cancer	5.07e-05	0.00012	CcSEcCtD
Escitalopram—Asthenia—Docetaxel—lung cancer	5.04e-05	0.000119	CcSEcCtD
Escitalopram—Infection—Methotrexate—lung cancer	5.03e-05	0.000119	CcSEcCtD
Escitalopram—Nausea—Etoposide—lung cancer	5.03e-05	0.000119	CcSEcCtD
Escitalopram—Ill-defined disorder—Doxorubicin—lung cancer	4.99e-05	0.000118	CcSEcCtD
Escitalopram—Pruritus—Docetaxel—lung cancer	4.97e-05	0.000118	CcSEcCtD
Escitalopram—Nervous system disorder—Methotrexate—lung cancer	4.97e-05	0.000117	CcSEcCtD
Escitalopram—Anaemia—Doxorubicin—lung cancer	4.97e-05	0.000117	CcSEcCtD
Escitalopram—Thrombocytopenia—Methotrexate—lung cancer	4.96e-05	0.000117	CcSEcCtD
Escitalopram—Agitation—Doxorubicin—lung cancer	4.94e-05	0.000117	CcSEcCtD
Escitalopram—Nausea—Paclitaxel—lung cancer	4.93e-05	0.000116	CcSEcCtD
Escitalopram—Skin disorder—Methotrexate—lung cancer	4.92e-05	0.000116	CcSEcCtD
Escitalopram—Hyperhidrosis—Methotrexate—lung cancer	4.9e-05	0.000116	CcSEcCtD
Escitalopram—Malaise—Doxorubicin—lung cancer	4.85e-05	0.000115	CcSEcCtD
Escitalopram—Vertigo—Doxorubicin—lung cancer	4.83e-05	0.000114	CcSEcCtD
Escitalopram—Anorexia—Methotrexate—lung cancer	4.83e-05	0.000114	CcSEcCtD
Escitalopram—Syncope—Doxorubicin—lung cancer	4.82e-05	0.000114	CcSEcCtD
Escitalopram—Leukopenia—Doxorubicin—lung cancer	4.81e-05	0.000114	CcSEcCtD
Escitalopram—Diarrhoea—Docetaxel—lung cancer	4.81e-05	0.000114	CcSEcCtD
Escitalopram—Palpitations—Doxorubicin—lung cancer	4.75e-05	0.000112	CcSEcCtD
Escitalopram—Hypotension—Methotrexate—lung cancer	4.74e-05	0.000112	CcSEcCtD
Escitalopram—Loss of consciousness—Doxorubicin—lung cancer	4.73e-05	0.000112	CcSEcCtD
Escitalopram—Cough—Doxorubicin—lung cancer	4.69e-05	0.000111	CcSEcCtD
Escitalopram—Convulsion—Doxorubicin—lung cancer	4.66e-05	0.00011	CcSEcCtD
Escitalopram—Dizziness—Docetaxel—lung cancer	4.65e-05	0.00011	CcSEcCtD
Escitalopram—Hypertension—Doxorubicin—lung cancer	4.64e-05	0.00011	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Methotrexate—lung cancer	4.62e-05	0.000109	CcSEcCtD
Escitalopram—Insomnia—Methotrexate—lung cancer	4.58e-05	0.000108	CcSEcCtD
Escitalopram—Chest pain—Doxorubicin—lung cancer	4.58e-05	0.000108	CcSEcCtD
Escitalopram—Myalgia—Doxorubicin—lung cancer	4.58e-05	0.000108	CcSEcCtD
Escitalopram—Arthralgia—Doxorubicin—lung cancer	4.58e-05	0.000108	CcSEcCtD
Escitalopram—Anxiety—Doxorubicin—lung cancer	4.56e-05	0.000108	CcSEcCtD
Escitalopram—Paraesthesia—Methotrexate—lung cancer	4.55e-05	0.000108	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	4.55e-05	0.000107	CcSEcCtD
Escitalopram—Discomfort—Doxorubicin—lung cancer	4.52e-05	0.000107	CcSEcCtD
Escitalopram—Dyspnoea—Methotrexate—lung cancer	4.52e-05	0.000107	CcSEcCtD
Escitalopram—Somnolence—Methotrexate—lung cancer	4.5e-05	0.000106	CcSEcCtD
Escitalopram—Dry mouth—Doxorubicin—lung cancer	4.48e-05	0.000106	CcSEcCtD
Escitalopram—Vomiting—Docetaxel—lung cancer	4.47e-05	0.000106	CcSEcCtD
Escitalopram—Dyspepsia—Methotrexate—lung cancer	4.46e-05	0.000105	CcSEcCtD
Escitalopram—Rash—Docetaxel—lung cancer	4.43e-05	0.000105	CcSEcCtD
Escitalopram—Dermatitis—Docetaxel—lung cancer	4.43e-05	0.000105	CcSEcCtD
Escitalopram—Confusional state—Doxorubicin—lung cancer	4.42e-05	0.000105	CcSEcCtD
Escitalopram—Decreased appetite—Methotrexate—lung cancer	4.41e-05	0.000104	CcSEcCtD
Escitalopram—Headache—Docetaxel—lung cancer	4.4e-05	0.000104	CcSEcCtD
Escitalopram—Anaphylactic shock—Doxorubicin—lung cancer	4.39e-05	0.000104	CcSEcCtD
Escitalopram—Oedema—Doxorubicin—lung cancer	4.39e-05	0.000104	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Methotrexate—lung cancer	4.37e-05	0.000103	CcSEcCtD
Escitalopram—Fatigue—Methotrexate—lung cancer	4.37e-05	0.000103	CcSEcCtD
Escitalopram—Infection—Doxorubicin—lung cancer	4.36e-05	0.000103	CcSEcCtD
Escitalopram—Pain—Methotrexate—lung cancer	4.33e-05	0.000102	CcSEcCtD
Escitalopram—Shock—Doxorubicin—lung cancer	4.32e-05	0.000102	CcSEcCtD
Escitalopram—Nervous system disorder—Doxorubicin—lung cancer	4.3e-05	0.000102	CcSEcCtD
Escitalopram—Thrombocytopenia—Doxorubicin—lung cancer	4.3e-05	0.000102	CcSEcCtD
Escitalopram—Tachycardia—Doxorubicin—lung cancer	4.28e-05	0.000101	CcSEcCtD
Escitalopram—Skin disorder—Doxorubicin—lung cancer	4.26e-05	0.000101	CcSEcCtD
Escitalopram—Hyperhidrosis—Doxorubicin—lung cancer	4.24e-05	0.0001	CcSEcCtD
Escitalopram—Anorexia—Doxorubicin—lung cancer	4.18e-05	9.89e-05	CcSEcCtD
Escitalopram—Nausea—Docetaxel—lung cancer	4.18e-05	9.87e-05	CcSEcCtD
Escitalopram—Feeling abnormal—Methotrexate—lung cancer	4.18e-05	9.87e-05	CcSEcCtD
Escitalopram—Gastrointestinal pain—Methotrexate—lung cancer	4.14e-05	9.79e-05	CcSEcCtD
Escitalopram—Hypotension—Doxorubicin—lung cancer	4.1e-05	9.69e-05	CcSEcCtD
Escitalopram—Urticaria—Methotrexate—lung cancer	4.03e-05	9.51e-05	CcSEcCtD
Escitalopram—Abdominal pain—Methotrexate—lung cancer	4.01e-05	9.47e-05	CcSEcCtD
Escitalopram—Body temperature increased—Methotrexate—lung cancer	4.01e-05	9.47e-05	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Doxorubicin—lung cancer	4e-05	9.45e-05	CcSEcCtD
Escitalopram—Insomnia—Doxorubicin—lung cancer	3.97e-05	9.38e-05	CcSEcCtD
Escitalopram—Paraesthesia—Doxorubicin—lung cancer	3.94e-05	9.31e-05	CcSEcCtD
Escitalopram—Dyspnoea—Doxorubicin—lung cancer	3.91e-05	9.25e-05	CcSEcCtD
Escitalopram—Somnolence—Doxorubicin—lung cancer	3.9e-05	9.22e-05	CcSEcCtD
Escitalopram—Dyspepsia—Doxorubicin—lung cancer	3.86e-05	9.13e-05	CcSEcCtD
Escitalopram—Decreased appetite—Doxorubicin—lung cancer	3.81e-05	9.02e-05	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Doxorubicin—lung cancer	3.79e-05	8.95e-05	CcSEcCtD
Escitalopram—Fatigue—Doxorubicin—lung cancer	3.78e-05	8.94e-05	CcSEcCtD
Escitalopram—Pain—Doxorubicin—lung cancer	3.75e-05	8.87e-05	CcSEcCtD
Escitalopram—Constipation—Doxorubicin—lung cancer	3.75e-05	8.87e-05	CcSEcCtD
Escitalopram—Hypersensitivity—Methotrexate—lung cancer	3.73e-05	8.82e-05	CcSEcCtD
Escitalopram—Asthenia—Methotrexate—lung cancer	3.64e-05	8.59e-05	CcSEcCtD
Escitalopram—Feeling abnormal—Doxorubicin—lung cancer	3.62e-05	8.55e-05	CcSEcCtD
Escitalopram—Gastrointestinal pain—Doxorubicin—lung cancer	3.59e-05	8.48e-05	CcSEcCtD
Escitalopram—Pruritus—Methotrexate—lung cancer	3.59e-05	8.47e-05	CcSEcCtD
Escitalopram—Urticaria—Doxorubicin—lung cancer	3.49e-05	8.24e-05	CcSEcCtD
Escitalopram—Abdominal pain—Doxorubicin—lung cancer	3.47e-05	8.2e-05	CcSEcCtD
Escitalopram—Body temperature increased—Doxorubicin—lung cancer	3.47e-05	8.2e-05	CcSEcCtD
Escitalopram—Diarrhoea—Methotrexate—lung cancer	3.47e-05	8.19e-05	CcSEcCtD
Escitalopram—Dizziness—Methotrexate—lung cancer	3.35e-05	7.92e-05	CcSEcCtD
Escitalopram—Hypersensitivity—Doxorubicin—lung cancer	3.23e-05	7.64e-05	CcSEcCtD
Escitalopram—Vomiting—Methotrexate—lung cancer	3.22e-05	7.62e-05	CcSEcCtD
Escitalopram—Rash—Methotrexate—lung cancer	3.2e-05	7.55e-05	CcSEcCtD
Escitalopram—Dermatitis—Methotrexate—lung cancer	3.19e-05	7.54e-05	CcSEcCtD
Escitalopram—Headache—Methotrexate—lung cancer	3.17e-05	7.5e-05	CcSEcCtD
Escitalopram—Asthenia—Doxorubicin—lung cancer	3.15e-05	7.44e-05	CcSEcCtD
Escitalopram—Pruritus—Doxorubicin—lung cancer	3.1e-05	7.34e-05	CcSEcCtD
Escitalopram—Nausea—Methotrexate—lung cancer	3.01e-05	7.11e-05	CcSEcCtD
Escitalopram—Diarrhoea—Doxorubicin—lung cancer	3e-05	7.1e-05	CcSEcCtD
Escitalopram—Dizziness—Doxorubicin—lung cancer	2.9e-05	6.86e-05	CcSEcCtD
Escitalopram—Vomiting—Doxorubicin—lung cancer	2.79e-05	6.59e-05	CcSEcCtD
Escitalopram—Rash—Doxorubicin—lung cancer	2.77e-05	6.54e-05	CcSEcCtD
Escitalopram—Dermatitis—Doxorubicin—lung cancer	2.76e-05	6.53e-05	CcSEcCtD
Escitalopram—Headache—Doxorubicin—lung cancer	2.75e-05	6.5e-05	CcSEcCtD
Escitalopram—Nausea—Doxorubicin—lung cancer	2.61e-05	6.16e-05	CcSEcCtD
Escitalopram—CYP2C19—Metabolism—ABCB1—lung cancer	1.06e-05	8.87e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—IL6R—lung cancer	1.06e-05	8.87e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CREBBP—lung cancer	1.06e-05	8.85e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—KDR—lung cancer	1.06e-05	8.81e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—NCOA3—lung cancer	1.05e-05	8.78e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—TYMS—lung cancer	1.04e-05	8.71e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—EGFR—lung cancer	1.04e-05	8.7e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GSTP1—lung cancer	1.03e-05	8.61e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—GSTM1—lung cancer	1.03e-05	8.61e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ADCY1—lung cancer	1.02e-05	8.54e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ABCG2—lung cancer	1.02e-05	8.54e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MAP2K1—lung cancer	1.01e-05	8.45e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PIK3CD—lung cancer	1.01e-05	8.39e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CAT—lung cancer	1.01e-05	8.38e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—HPGDS—lung cancer	1e-05	8.38e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ENO2—lung cancer	1e-05	8.38e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PPP2R1B—lung cancer	9.99e-06	8.33e-05	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—PIK3CA—lung cancer	9.97e-06	8.31e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—KIT—lung cancer	9.92e-06	8.27e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—APC—lung cancer	9.92e-06	8.27e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PIK3CG—lung cancer	9.92e-06	8.27e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—NRAS—lung cancer	9.92e-06	8.27e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PIK3CG—lung cancer	9.89e-06	8.25e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—APC—lung cancer	9.89e-06	8.25e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—KIT—lung cancer	9.89e-06	8.25e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—NRAS—lung cancer	9.89e-06	8.25e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—KRAS—lung cancer	9.86e-06	8.22e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—EGF—lung cancer	9.81e-06	8.18e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CYP1A1—lung cancer	9.79e-06	8.16e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—ABCB1—lung cancer	9.78e-06	8.15e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—EGF—lung cancer	9.78e-06	8.15e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GSTT1—lung cancer	9.75e-06	8.13e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—KIT—lung cancer	9.74e-06	8.12e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PIK3CG—lung cancer	9.74e-06	8.12e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—APC—lung cancer	9.74e-06	8.12e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—NRAS—lung cancer	9.74e-06	8.12e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—ERCC2—lung cancer	9.71e-06	8.09e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GCLC—lung cancer	9.63e-06	8.03e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CYP2A6—lung cancer	9.63e-06	8.03e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—EGF—lung cancer	9.63e-06	8.02e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—TYMS—lung cancer	9.61e-06	8.01e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—MAPK3—lung cancer	9.5e-06	7.92e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GSTM1—lung cancer	9.5e-06	7.92e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—MAPK3—lung cancer	9.47e-06	7.9e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—POMC—lung cancer	9.45e-06	7.87e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—POMC—lung cancer	9.42e-06	7.85e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—BRAF—lung cancer	9.33e-06	7.78e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—MAPK3—lung cancer	9.33e-06	7.77e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—BRAF—lung cancer	9.3e-06	7.75e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—POMC—lung cancer	9.27e-06	7.73e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—IL6R—lung cancer	9.22e-06	7.68e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CREBBP—lung cancer	9.2e-06	7.67e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—IL6R—lung cancer	9.19e-06	7.66e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CREBBP—lung cancer	9.17e-06	7.65e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—BRAF—lung cancer	9.15e-06	7.63e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ENO1—lung cancer	9.13e-06	7.61e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—PIK3CA—lung cancer	9.06e-06	7.55e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—IL6R—lung cancer	9.04e-06	7.54e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—EGFR—lung cancer	9.04e-06	7.54e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CREBBP—lung cancer	9.03e-06	7.53e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MDM2—lung cancer	9.02e-06	7.52e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—EGFR—lung cancer	9.01e-06	7.51e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CYP1A1—lung cancer	9e-06	7.5e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—RAF1—lung cancer	8.99e-06	7.49e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—ERCC2—lung cancer	8.93e-06	7.44e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—ERBB2—lung cancer	8.89e-06	7.41e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—EGFR—lung cancer	8.87e-06	7.4e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MAP2K1—lung cancer	8.78e-06	7.32e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MTOR—lung cancer	8.78e-06	7.32e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PIK3CB—lung cancer	8.78e-06	7.32e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MAP2K1—lung cancer	8.75e-06	7.3e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PIK3CD—lung cancer	8.72e-06	7.27e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PIK3CD—lung cancer	8.7e-06	7.25e-05	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—PIK3CA—lung cancer	8.64e-06	7.2e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MAP2K1—lung cancer	8.62e-06	7.18e-05	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—PIK3CA—lung cancer	8.61e-06	7.18e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PIK3CD—lung cancer	8.56e-06	7.14e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—KRAS—lung cancer	8.54e-06	7.12e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—KRAS—lung cancer	8.51e-06	7.1e-05	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—PIK3CA—lung cancer	8.48e-06	7.07e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CXCL8—lung cancer	8.43e-06	7.03e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—APOA1—lung cancer	8.4e-06	7e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—KRAS—lung cancer	8.38e-06	6.99e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—HRAS—lung cancer	8.38e-06	6.98e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CYP2E1—lung cancer	8.19e-06	6.83e-05	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—AKT1—lung cancer	8.15e-06	6.79e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—NQO1—lung cancer	8.1e-06	6.75e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CASP3—lung cancer	8.07e-06	6.73e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—IL2—lung cancer	8.06e-06	6.72e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	8.04e-06	6.7e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—IL6—lung cancer	8.02e-06	6.69e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CCND1—lung cancer	7.86e-06	6.55e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—PIK3CA—lung cancer	7.85e-06	6.54e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—JUN—lung cancer	7.84e-06	6.54e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—PIK3CA—lung cancer	7.82e-06	6.52e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MDM2—lung cancer	7.82e-06	6.52e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MDM2—lung cancer	7.79e-06	6.49e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—RAF1—lung cancer	7.79e-06	6.49e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—RAF1—lung cancer	7.76e-06	6.47e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—APOA1—lung cancer	7.72e-06	6.44e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—ERBB2—lung cancer	7.71e-06	6.42e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—PIK3CA—lung cancer	7.7e-06	6.42e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—ERBB2—lung cancer	7.68e-06	6.4e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MDM2—lung cancer	7.67e-06	6.39e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PIK3CG—lung cancer	7.67e-06	6.39e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—RAF1—lung cancer	7.64e-06	6.37e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MMP9—lung cancer	7.63e-06	6.36e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PIK3CB—lung cancer	7.6e-06	6.34e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MTOR—lung cancer	7.6e-06	6.34e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CDKN1A—lung cancer	7.6e-06	6.34e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PTEN—lung cancer	7.58e-06	6.32e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MTOR—lung cancer	7.58e-06	6.32e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PIK3CB—lung cancer	7.58e-06	6.32e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—ERBB2—lung cancer	7.56e-06	6.3e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PIK3CB—lung cancer	7.46e-06	6.22e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MTOR—lung cancer	7.46e-06	6.22e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—AKT1—lung cancer	7.4e-06	6.17e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CXCL8—lung cancer	7.31e-06	6.09e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—STK11—lung cancer	7.3e-06	6.09e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—POMC—lung cancer	7.3e-06	6.08e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CXCL8—lung cancer	7.28e-06	6.07e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—HRAS—lung cancer	7.26e-06	6.05e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—HRAS—lung cancer	7.24e-06	6.03e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—EP300—lung cancer	7.23e-06	6.03e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CXCL8—lung cancer	7.17e-06	5.98e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—HRAS—lung cancer	7.12e-06	5.94e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CREBBP—lung cancer	7.11e-06	5.93e-05	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—AKT1—lung cancer	7.06e-06	5.88e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PIK3CG—lung cancer	7.05e-06	5.88e-05	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—AKT1—lung cancer	7.04e-06	5.87e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—SRC—lung cancer	7.03e-06	5.86e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CASP3—lung cancer	6.99e-06	5.83e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—IL2—lung cancer	6.98e-06	5.82e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CASP3—lung cancer	6.97e-06	5.81e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—IL2—lung cancer	6.96e-06	5.8e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—IL6—lung cancer	6.95e-06	5.79e-05	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—AKT1—lung cancer	6.93e-06	5.77e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—IL6—lung cancer	6.93e-06	5.77e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CASP3—lung cancer	6.86e-06	5.72e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—IL2—lung cancer	6.85e-06	5.71e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—VEGFA—lung cancer	6.85e-06	5.71e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—IL6—lung cancer	6.82e-06	5.68e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CCND1—lung cancer	6.81e-06	5.68e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—JUN—lung cancer	6.79e-06	5.66e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CCND1—lung cancer	6.79e-06	5.66e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—STAT3—lung cancer	6.78e-06	5.65e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—JUN—lung cancer	6.77e-06	5.65e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—NRAS—lung cancer	6.77e-06	5.64e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GSTP1—lung cancer	6.76e-06	5.63e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PIK3CD—lung cancer	6.74e-06	5.62e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—POMC—lung cancer	6.71e-06	5.6e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CCND1—lung cancer	6.68e-06	5.57e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—JUN—lung cancer	6.67e-06	5.56e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—ALB—lung cancer	6.65e-06	5.55e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MMP9—lung cancer	6.61e-06	5.51e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MMP9—lung cancer	6.59e-06	5.49e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CDKN1A—lung cancer	6.59e-06	5.49e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CAT—lung cancer	6.57e-06	5.48e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PTEN—lung cancer	6.57e-06	5.48e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CDKN1A—lung cancer	6.56e-06	5.47e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PTEN—lung cancer	6.55e-06	5.46e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CREBBP—lung cancer	6.54e-06	5.45e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MMP9—lung cancer	6.49e-06	5.41e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MAPK3—lung cancer	6.48e-06	5.4e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CDKN1A—lung cancer	6.46e-06	5.39e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PTEN—lung cancer	6.45e-06	5.38e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—AKT1—lung cancer	6.41e-06	5.34e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ABCB1—lung cancer	6.4e-06	5.33e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—AKT1—lung cancer	6.39e-06	5.33e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MYC—lung cancer	6.3e-06	5.25e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—AKT1—lung cancer	6.29e-06	5.24e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—TYMS—lung cancer	6.28e-06	5.24e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—EP300—lung cancer	6.27e-06	5.22e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—EP300—lung cancer	6.25e-06	5.21e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GSTM1—lung cancer	6.21e-06	5.18e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PIK3CD—lung cancer	6.2e-06	5.17e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—EGFR—lung cancer	6.16e-06	5.14e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—EP300—lung cancer	6.15e-06	5.13e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—ALB—lung cancer	6.12e-06	5.1e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—SRC—lung cancer	6.09e-06	5.08e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—SRC—lung cancer	6.07e-06	5.06e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—SRC—lung cancer	5.98e-06	4.98e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—VEGFA—lung cancer	5.94e-06	4.95e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—VEGFA—lung cancer	5.92e-06	4.93e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CYP1A1—lung cancer	5.89e-06	4.91e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—STAT3—lung cancer	5.88e-06	4.9e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PIK3CB—lung cancer	5.87e-06	4.9e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—NRAS—lung cancer	5.86e-06	4.89e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—STAT3—lung cancer	5.86e-06	4.88e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—NRAS—lung cancer	5.84e-06	4.87e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ERCC2—lung cancer	5.84e-06	4.87e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—VEGFA—lung cancer	5.82e-06	4.86e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—KRAS—lung cancer	5.82e-06	4.85e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PTGS2—lung cancer	5.82e-06	4.85e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—STAT3—lung cancer	5.77e-06	4.81e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—NRAS—lung cancer	5.75e-06	4.8e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MAPK3—lung cancer	5.61e-06	4.68e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MAPK3—lung cancer	5.6e-06	4.67e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MAPK3—lung cancer	5.51e-06	4.59e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MYC—lung cancer	5.46e-06	4.55e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MYC—lung cancer	5.44e-06	4.54e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PIK3CB—lung cancer	5.4e-06	4.5e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MYC—lung cancer	5.36e-06	4.47e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PTGS2—lung cancer	5.35e-06	4.46e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PIK3CA—lung cancer	5.35e-06	4.46e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—EGFR—lung cancer	5.34e-06	4.45e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—EGFR—lung cancer	5.32e-06	4.44e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—EGFR—lung cancer	5.24e-06	4.37e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—TP53—lung cancer	5.18e-06	4.31e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PTEN—lung cancer	5.08e-06	4.23e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—APOA1—lung cancer	5.05e-06	4.21e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—KRAS—lung cancer	5.05e-06	4.21e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—KRAS—lung cancer	5.03e-06	4.19e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—KRAS—lung cancer	4.95e-06	4.13e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—HRAS—lung cancer	4.95e-06	4.13e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—EP300—lung cancer	4.84e-06	4.04e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—IL6—lung cancer	4.74e-06	3.95e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PTEN—lung cancer	4.67e-06	3.89e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PIK3CA—lung cancer	4.64e-06	3.86e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PIK3CA—lung cancer	4.62e-06	3.85e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PIK3CG—lung cancer	4.61e-06	3.84e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PIK3CA—lung cancer	4.55e-06	3.79e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TP53—lung cancer	4.48e-06	3.74e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TP53—lung cancer	4.47e-06	3.73e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—EP300—lung cancer	4.45e-06	3.71e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TP53—lung cancer	4.4e-06	3.67e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—POMC—lung cancer	4.39e-06	3.66e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—AKT1—lung cancer	4.37e-06	3.64e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—HRAS—lung cancer	4.29e-06	3.58e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—HRAS—lung cancer	4.28e-06	3.56e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CREBBP—lung cancer	4.27e-06	3.56e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—HRAS—lung cancer	4.21e-06	3.51e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—IL6—lung cancer	4.1e-06	3.42e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—IL6—lung cancer	4.09e-06	3.41e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PIK3CD—lung cancer	4.05e-06	3.38e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—IL6—lung cancer	4.03e-06	3.36e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ALB—lung cancer	4e-06	3.34e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—AKT1—lung cancer	3.79e-06	3.16e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—AKT1—lung cancer	3.77e-06	3.15e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—AKT1—lung cancer	3.72e-06	3.1e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PIK3CA—lung cancer	3.58e-06	2.99e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PIK3CB—lung cancer	3.53e-06	2.94e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PTGS2—lung cancer	3.5e-06	2.92e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PIK3CA—lung cancer	3.29e-06	2.75e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PTEN—lung cancer	3.05e-06	2.54e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—AKT1—lung cancer	2.93e-06	2.44e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—EP300—lung cancer	2.91e-06	2.43e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—AKT1—lung cancer	2.69e-06	2.24e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PIK3CA—lung cancer	2.15e-06	1.8e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—AKT1—lung cancer	1.76e-06	1.47e-05	CbGpPWpGaD
